Inactivation of the p53 pathway in retinoblastoma

Nature

Volumn 444, Issue 7115, 2006, Pages 61-66

  Laurie, Nikia A ^a   Donovan, Stacy L ^a   Shih, Chie Schin ^a   Zhang, Jiakun ^a   Mills, Nicholas ^a,b   Fuller, Christine ^a   Teunisse, Amina ^c   Lam, Suzanne ^c   Ramos, Yolande ^c   Mohan, Adithi ^a   Johnson, Dianna ^d   Wilson, Matthew ^a,d   Rodriguez Galindo, Carlos ^a   Quarto, Micaela ^e   Francoz, Sarah ^f   Mendrysa, Susan M ^g   Guy, R Kiplin ^a   Marine, Jean Christophe ^f   Jochemsen, Aart G ^c   Dyer, Michael A ^a,d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^g PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHEMOTHERAPY; GENES; MUTAGENS; PROTEINS; TUMORS;

DEATH-RESISTANT CELLS; GENETIC MUTATIONS; MDMX GENE; RETINOGENESIS;

GENETIC ENGINEERING;

PROTEIN P53;

APOPTOSIS; CANCER; EYE; GENE EXPRESSION; MUTATION; PROTEIN; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MDMX; GENE MUTATION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA DEVELOPMENT; RETINOBLASTOMA;

EID: 33750590095     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05194     Document Type: Article

References (36)

1. Hahn, W. C. & Weinberg, R. A. Modelling the molecular circuitry of cancer. Nature Rev. Cancer 2, 331-341 (2002).
2. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789-799 (2004).
3. Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103-112 (2002).
4. Chau, B. N. & Wang, J. Y. Coordinated regulation of life and death by RB. Nature Rev. Cancer 3, 130-138 (2003).
5. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
6. Oren, M. Decision making by p53: life, death and cancer. Cell Death Differ. 10, 431-442 (2003).
7. Prives, C. & Hall, P. A. The p53 pathway. J. Pathol. 187, 112-126 (1999).
8. Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997).
9. Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997).
10. Momand, J., Jung, D., Wilczynski, S. & Niland, J. The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459 (1998).
11. Yang, Y. et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7, 547-559 (2005).
12. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
13. Kato, M. V. et al. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett. 106, 75-82 (1996).
14. Nork, T. M., Poulsen, G. L., Millecchia, L. L., Jantz, R. G. & Nickells, R. W. p53 regulates apoptosis in human retinoblastoma. Arch. Ophthalmol. 115, 213-219 (1997).
15. Chen, D. et al. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 5, 539-551 (2004).
16. Dyer, M. A. & Bremner, R. The search for the retinoblastoma cell of origin. Nature Rev. Cancer 5, 91-101 (2005).
17. Aslanian, A., Iaquinta, P. J., Verona, R. & Lees, J. A. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev. 18, 1413-1422 (2004).
18. Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77-83 (2003).
19. Zhang, J., Schweers, B. & Dyer, M. A. The first knockout mouse model of retinoblastoma. Cell Cycle 3, 952-959 (2004).
20. Donovan, S., Schweers, B., Martins, R., Johnson, D. & Dyer, M. A. Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biol. 4, 14 (2006).
21. Shvarts, A. et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 15, 5349-5357 (1996).
22. Danovi, D. et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 24, 5835-5843 (2004).
23. McKenzie, P. P., McPake, C. R., Ashford, A. A., Vanin, E. F. & Harris, L. C. MDM2 does not influence p53-mediated sensitivity to DNA-damaging drugs. Mol. Cancer Ther. 1, 1097-1104 (2002).
24. Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679 (1998).
25. Kastan, M. B., Lim, D. S., Kim, S. T. & Yang, D. ATM-akey determinant of multiple cellular responses to irradiation. Acta Oncol. 40, 686-688 (2001).
26. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
27. Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553 (2002).
28. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915 (1990).
29. Robanus-Maandag, E. et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev. 12, 1599-1609 (1998).
30. MacPherson, D. et al. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev. 18, 1681-1694 (2004).
31. Dyer, M. A. & Harbour, J. W. in Clinical Ocular Oncology Ch. 66 (eds Singh, A. D., Damato, B., Murphree, A. L. & Perry, J. D.) (Elsevier, London, in the press).
32. Dyer, M. A., Rodriguez-Galindo, C. & Wilson, M. W. Use of preclinical models to improve treatment of retinoblastoma. PLoS Med. 2, e332 (2005).
33. Marquardt, T. et al. Pax6 is required for the multipotent state of retinal progenitor cells. Cell 105, 43-55 (2001).
34. Lu, F. et al. Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. J. Comb. Chem. 8, 315-325 (2006).
35. Dang, J. et al. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 62, 1222-1230 (2002).
36. Laurie, N. A. et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin. Cancer Res. 11, 7569-7578 (2005).